Ecor1 Capital buys $32,470,825 stake in Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (IRWD) : Ecor1 Capital scooped up 369,034 additional shares in Ironwood Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,430,451 shares of Ironwood Pharmaceuticals which is valued at $32,470,825.Ironwood Pharmaceuticals makes up approximately 14.01% of Ecor1 Capital’s portfolio.

Other Hedge Funds, Including , Everpoint Asset Management boosted its stake in IRWD in the latest quarter, The investment management firm added 360,000 additional shares and now holds a total of 2,710,000 shares of Ironwood Pharmaceuticals which is valued at $36,205,600. Ironwood Pharmaceuticals makes up approx 0.95% of Everpoint Asset Management’s portfolio.Teachers Advisors Inc boosted its stake in IRWD in the latest quarter, The investment management firm added 23,369 additional shares and now holds a total of 221,344 shares of Ironwood Pharmaceuticals which is valued at $2,957,156.Tower Research Capital (trc) boosted its stake in IRWD in the latest quarter, The investment management firm added 3,154 additional shares and now holds a total of 3,682 shares of Ironwood Pharmaceuticals which is valued at $49,192.Alps Advisors Inc boosted its stake in IRWD in the latest quarter, The investment management firm added 37,144 additional shares and now holds a total of 180,481 shares of Ironwood Pharmaceuticals which is valued at $2,636,827. Ironwood Pharmaceuticals makes up approx 0.02% of Alps Advisors Inc’s portfolio.

Ironwood Pharmaceuticals opened for trading at $13.35 and hit $13.48 on the upside on Thursday, eventually ending the session at $13.35, with a gain of 0.07% or 0.01 points. The heightened volatility saw the trading volume jump to 5,33,355 shares. Company has a market cap of $1,940 M.

On the company’s financial health, Ironwood Pharmaceuticals reported $-0.16 EPS for the quarter, based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus estimate of $-0.16. The company had revenue of $54.40 million for the quarter, compared to analysts expectations of $54.49 million. The company’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.34 EPS.

Many Wall Street Analysts have commented on Ironwood Pharmaceuticals. Company shares were Reiterated by Mizuho on Jul 15, 2016 to “Buy”, Firm has raised the Price Target to $ 24 from a previous price target of $16 .

Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Leave a Reply

Ironwood Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Ironwood Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.